Peregrine's (PPHM) Phase Ib IST of Bavituximab Important Progress in Development as NSCLC Treatment - Roth
Tweet Send to a Friend
Roth Capital affirms Peregrine Pharmaceuticals (Nasdaq: PPHM) at Buy with a price target of $5 after the company announced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
